Objectives: Non-muscle-invasive bladder cancer is characterized by a high recurrence rate after primary transurethral resection.
In case of bacillus Calmette-Guérin-refractory neoplasms, cystectomy is the gold standard. In this study the effects of thermochemotherapy with mitomycin C were evaluated in high-risk bladder cancer nonresponders to previous therapy.
Patients and Methods: Between January 2006 and December 2009, 30 patients were enrolled with recurrent stage carcinoma in situ, Ta and T1, grade G1 to G3 non-muscle-invasive bladder cancer refractory to chemotherapy or immunotherapy and so becoming suitable for radical cystectomy. All patients underwent endovesical thermochemotherapy: 16 patients underwent a prophylactic scheme and 14 patients underwent an ablative scheme.
Results: All the patients completed the study. The mean follow-up for all the patients enrolled was 14 months. Thirteen of 30 patients (43.30%) were disease free and 17 patients (56.70%) had recurrence. In the prophylactic group, 7 of 16 patients (43.75%) were disease free and 9 patients (46.25%) had tumor recurrence; no progression was observed. In the ablative group, 3 patients (17, 64%) had progression to muscle-invasive disease. Side effects were generally mild.
Conclusions: Thermochemotherapy could be considered an additional tool in patients refractory to intravesical therapies before considering early cystectomy.
Written by:
Volpe A, Racioppi M, Bongiovanni L, D'Agostino D, Totaro A, D'Addessi A, Marangi F, Palermo G, Pinto F, Sacco E, Bassi PF. Are you the author?
Department of Urology, Catholic University of the Sacred Heart, Rome, Italy.
Reference: Urol Int. 2012 Sep 7. Epub ahead of print.
doi: 10.1159/000341912
PubMed Abstract
PMID: 22965159
UroToday.com Bladder Cancer Section
